Literature DB >> 18284271

The costs of schizophrenia.

Joseph P McEvoy1.   

Abstract

Reasonably accurate approximations of the financial costs of schizophrenia are the foundation for making judgments about the socioeconomic impact of the disorder and the cost-effectiveness of treatment modalities. The financial costs of schizophrenia to society can be divided into direct and indirect costs. Direct costs include treatment provided in inpatient, outpatient, and long-term care, as well as criminal justice costs, medication costs, and publicly owned capital such as state mental health facilities. Indirect costs mostly arise from the productivity loss suffered by individuals with schizophrenia, family members, and caregivers. The cost of schizophrenia in the United States in 2002 was estimated to be $62.7 billion. Compared with a 1991 estimate, inpatient costs have declined, whereas outpatient costs and medication costs have increased. When interpreting any data regarding costs, people should be aware of factors that influence results, such as the perspective from which the analysis was undertaken, the measures used in the analysis, and planned or unplanned bias.

Entities:  

Mesh:

Year:  2007        PMID: 18284271

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  32 in total

Review 1.  Neuroimaging correlates of aggression in schizophrenia: an update.

Authors:  Matthew J Hoptman; Daniel Antonius
Journal:  Curr Opin Psychiatry       Date:  2011-03       Impact factor: 4.741

2.  Comparison of health services use associated with ziprasidone and olanzapine among schizophrenia and bipolar disorder patients in the USA.

Authors:  Yawen Jiang; Weiyi Ni; Justin J McGinnis
Journal:  Clin Drug Investig       Date:  2014-07       Impact factor: 2.859

Review 3.  Impulsivity and aggression in schizophrenia: a neural circuitry perspective with implications for treatment.

Authors:  Matthew J Hoptman
Journal:  CNS Spectr       Date:  2015-04-22       Impact factor: 3.790

Review 4.  The Societal Cost of Schizophrenia: A Systematic Review.

Authors:  Huajie Jin; Iris Mosweu
Journal:  Pharmacoeconomics       Date:  2017-01       Impact factor: 4.981

5.  Health status and mobility limitations are associated with residential and employment status in schizophrenia and bipolar disorder.

Authors:  M Strassnig; D Cornacchio; P D Harvey; R Kotov; L Fochtmann; E J Bromet
Journal:  J Psychiatr Res       Date:  2017-07-18       Impact factor: 4.791

Review 6.  Electroconvulsive therapy: Part I. A perspective on the evolution and current practice of ECT.

Authors:  Nancy A Payne; Joan Prudic
Journal:  J Psychiatr Pract       Date:  2009-09       Impact factor: 1.325

7.  Embracing Psychosis: A Cognitive Insight Intervention Improves Personal Narratives and Meaning-Making in Patients With Schizophrenia.

Authors:  Steffen Moritz; Candelaria I Mahlke; Stefan Westermann; Friederike Ruppelt; Paul H Lysaker; Thomas Bock; Christina Andreou
Journal:  Schizophr Bull       Date:  2018-02-15       Impact factor: 9.306

8.  Clozapine attenuates disruptions in response inhibition and task efficiency induced by repeated phencyclidine administration in the intracranial self-stimulation procedure.

Authors:  Nurith Amitai; Svetlana Semenova; Athina Markou
Journal:  Eur J Pharmacol       Date:  2008-11-09       Impact factor: 4.432

9.  Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia.

Authors:  Douglas E Faries; Haya Ascher-Svanum; Allen W Nyhuis; Bruce J Kinon
Journal:  BMC Psychiatry       Date:  2009-09-02       Impact factor: 3.630

10.  Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia.

Authors:  Haya Ascher-Svanum; Allen W Nyhuis; Douglas E Faries; Daniel E Ball; Bruce J Kinon
Journal:  BMC Psychiatry       Date:  2010-01-28       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.